[Clinical Features and Prognostic of Patients with Primary Central Nervous System Lymphoma].

Autor:	Zhang LT; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Li CC; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Jin QQ; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Jiang HY; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Yue NN; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Zeng PY; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Yue LL; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China., Wu CY; The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China. E-mail: wuchy0909@163.com.
Jazyk:	čínština
Zdroj:	Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2024 Jun; Vol. 32 (3), pp. 723-732.
DOI:	10.19746/j.cnki.issn.1009-2137.2024.03.011
Abstrakt:	Objective: To explore the clinical features and prognosis of patients with primary central nervous system lymphoma（PCNSL）. Methods: A retrospective analysis was performed on the relationship between clinical features, treatment regimen and prognosis in 46 newly diagnosed patients with primary central nervous system lymphoma who were diagnosed and treated in The Second Hospital of Lanzhou University from January 2015 to September 2022. Fisher's exact probability method was used to analyze the differences in clinical data of different subgroups. Kaplan-Meier survival curve was used to analyze the overall survival rate and progression-free survival rate of patients with different treatments, and the factors influencing survival were analyzed. Results: Among 46 patients with PCNSL, which pathological type were diffuse large B-cell lymphoma（DLBCL）. There were 26(56.5%) cases of male and 20(43.5%) of female, with a median age of 54(17-71) years. In Hans subtypes, 14 cases (30.4%) of GCB subtype, 32 cases (69.6%) of non-GCB subtype. 32 cases (69.6%) of Ki-67≥80%. Among 36 patients who completed at least 2 cycles of treatment with follow-up data, the efficacy evaluation was as follows: overall response rate(ORR) was 63.9%, complete response(CR) rate was 47.2%, 17 cases of CR, 6 cases of PR. The 1-year progression-free survival rate and 1-year overall survival rate was 73.6% and 84.9%, respectively. The 2-year progression-free survival rate and 2-year overall survival rate was 52.2% and 68.9%, respectively. The ORR and CR rate of 17 patients treated with RMT regimen was 76.5% and 52.9% (9 cases CR and 4 cases PR), respectively. Univariate analysis of 3 groups of patients treated with RMT regimen, RM-BTKi regimen, and RM-TT regimen as first-line treament showed that deep brain infiltration was associated with adverse PFS( P =0.032), and treatment regimen was associated with adverse OS in PCNSL patients（ P =0.025）. Conclusion: Different treatment modalities were independent prognosis predictors for OS, the deep brain infiltration of PCNSL is a poor predictive factor for PFS. Patients with relapse/refractory (R/R) PCNSL have a longer overall survival time because to the novel medication BTKi. They have strong toleration and therapeutic potential as a first-line therapy for high-risk patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu